Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin prophylaxis for prevention of risperidone-induced hyperprolactinemia in children and adolescents
IRCT20200304046698N2Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of metformin and risperidone in hyperprolactinemia (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Hyperprolactinemia. Started Jun 2024; status: completed.
02
Drugs
metforminrisperidone
03
Conditions
hyperprolactinemia
Beyond the preview
Go deeper on IRCT20200304046698N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200304046698N2.